A phase I, randomised, double-blind, placebo-controlled single ascending dose (SAD) trial of PL265.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs PL 265 (Primary)
- Indications Cancer pain; Dry eyes; Neuropathic pain; Ocular pain
- Focus Adverse reactions; First in man
- 29 Jun 2017 Results published in a Pharmaleads media release.
- 11 May 2017 New trial record